6 participants
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2024-06-28
- Start Date:
- 2021-06-06
- Completion:
- 2023-10-11
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
- GENETIC
- BIOLOGICAL
- DRUG
No Results Yet